Publication-only abstracts (abstract number preceded by an "e"), published in conjunction with the 2018 ASCO Annual Meeting but not presented at the Meeting, can be found online only.
EGFR, MUC-1 and PD-L1 expressions in cases with triple negative breast cancer (TNBC).
2018 ASCO Annual Meeting
J Clin Oncol 36, 2018 (suppl; abstr e12584)
Author(s): Semra Paydas, Cem Mirili, Emine Bagir, Gulsah Seydaoglu, Ali Oğul, Mahmut Büyüksimsek, Abdullah Evren Yetisir, Bilgin Karaalioglu, Mert Tohumcuoglu; Cukurova University Faculty of Medicine, Department of Oncology, Adana, Turkey; Cukurova University Faculty of Medicine, Department of Pathology, Adana, Turkey; Cukurova University Faculty of Medicine, Department of Biostatistics And Medical Science, Adana, Turkey
Background: Immune checkpoint ligand PD-L1 and transmembrane oncogenic protein MUC-1 are upragulated in TNBC and contribute aggressive behavior of this disease. It has been shown that pharmacologic targeting of MUC-1 suppress the PD-L1 expression in cell lines. The aim of this study is to explore the association between MUC-1, PD-L1 and EGFR expressions in tumor samples and to compare them with survival times and also possible role of therapeutic targeting of these molecules Methods: MUC-1, EGFR and PD-L1 expressions were detected by immunohistochemistry in cases with TNBC. Clinical and prognostic parameters were compared with MUC-1, EGFR and PD-L1 expressions Results: 97 cases with TNBC were evaluated; 17 of them had stage I, 47 had stage II, 27 had stage III and 6 had stage IV disease. All of the cases had been treated by anthracycline and taxane containing regimens. MUC-1, EGFR and PD-L1 were detected in 34, 61 and 17 cases, respectively. PFS and OS were found to be longer in cases with EGFR expression and MUC-1 and EGFR double expressors for MUC-1 and EGFR. Table 1 shows PFS and OS times according to the EGFR, MUC-1 and PDL-1 expressions. EGFR was found to be significant in Cox regression analysis. Conclusions: EGFR was found to be the most important prognostic indicator in patients with TNBC.
1. TAILORx: Phase III trial of chemoendocrine therapy versus endocrine therapy alone in hormone receptor-positive, HER2-negative, node-negative breast cancer and an intermediate prognosis 21-gene recurrence score.